Now at startup Aulos Biosciences, former Five Prime CEO Aron Knickerbocker is ready for new cancer challenge bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to develop oncology and immunology treatments.
The man making antibodies smarter globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
News provided by
Share this article
Share this article
LARKSPUR, Calif., May 17, 2021 /PRNewswire/ Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Leo Redmond will join the company as chief financial officer. Redmond brings to Aulos nearly three decades of financial experience in the biopharmaceutical industry. He will be based in the company s new headquarters in Larkspur, California. We are pleased to welcome Leo to Aulos at a time when we are rapidly building out our operations in California, preparing to start our first human trial of AU-007, planning our next fundraising scenarios, and defining the corporate strategy. Leo is a wonderful addition to our leadership team. His knowledge and expertise in leading all aspects of financial management for both private and public bi
16%
Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Beginning in 2021, non-GAAP measures exclude gains and losses on investments in equity securities and 2020 amounts have been reclassified for comparability. The company s 2021 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company s business.